TL10: Evaluation of the Risk Prediction Performance of Biomarkers and Tests
*Yuying Jin, FDA/CDRH Keywords: There are increasing interests in assessing the risk prediction performance of noval biomarkers and tests. The related clinical practices include quantifying the cardiovascular disease risk, predicting cancer recurrence, etc. In order to evaluate the risk, it is crucial to have an appropriate study design, an representative risk population and utilize proper statistical methodologies. During this roundtable, participants can share their experience in designing a clinical study for risk assessment. Furthermore, participants can discusss current statistical methods/models for evaluating the performance.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC